Mechanistically, erlotinib enhances gemcitabine induced tumor cell apoptosis by inhibiting the EGFR signaling pathway and downregulating BRCA1 mediated DNA repair ability (Moore et al., 2007). This evidence concerns the gene BRCA1 and neoplasm.